Summary:
The standard source of hemopoietic progenitor cells for allogeneic transplants has been bone marrow (allo-BMT). However, allogeneic transplantation of G-CSF mobilized peripheral blood progenitor cells (allo-PBT) is being increasingly used, since it is a more comfortable method for the donor and is associated with a quicker engraftment in the recipient. 1 Thus, whereas until 1993 only three cases of allo-PBT had been reported worldwide, [2] [3] [4] in 1999 it represented 46% of the total number of allogeneic transplants performed in Europe. 5 Whether or not allo-PBT will substitute allo-BMT is a matter of debate. A major concern with allo-PBT is the high incidence of chronic GVHD. [6] [7] [8] [9] [10] [11] In allo-BMT, the balance between the antileukemic effect and the mortality associated with chronic GVHD has been reported to be more favorable for patients transplanted in advanced disease than for those transplanted in early disease. 12 This could also be the case with allo-PBT. 13 Although it has been shown in some studies that in patients with advanced disease transplant-related mortality (TRM) and disease-free survival (DFS) are better with allo-PBT than with allo-BMT, 9 ,14 these results have not been confirmed in individuals transplanted in early phase. 9, 14, 15 For patients submitted to allo-PBT in early phase, the use of T cell depletion of the graft (TCD) might improve the outcome by maintaining a rapid engraftment without the offset of a high incidence of chronic GVHD. 16 With recent progress in cell separation technology, simple, automated and reproducible methods of TCD by positively selecting CD34 ϩ hematopoietic progenitors are available. 17, 18 We have previously shown that allogeneic transplantation of CD34 ϩ -selected cells from G-CSF mobilized peripheral blood progenitor cells (allo-PBT/CD34
ϩ ) results in a rapid engraftment without significant GVHD. 19 Whereas these results have been confirmed in some studies, 20, 21 in others severe GVHD has been reported. 22, 23 However, all these studies are preliminary and include a limited number of patients; none of them has compared the potential clinical benefit of allo-PBT/CD34 ϩ with unmodified allo-PBT.
Patients, donors and methods

Patients
Fifty consecutive patients diagnosed with acute myeloid leukemia in first complete remission (AML CR1) (n ϭ 29), refractory anemia with excess of blasts (RAEB) (n ϭ 2), refractory anemia with excess of blasts in transformation (RAEBt) (n ϭ 2), or chronic myeloid leukemia in first chronic phase (CML CP1) (n ϭ 17) were submitted to allo-PBT/CD34
ϩ from an HLA identical sibling donor, as a first transplant, in 15 Spanish hospitals between March 1995 and October 1998. Last follow-up of the patients was performed in April 2001. Patient characteristics are shown in Table 1 . Allo-PBT/CD34 + = allogeneic peripheral blood transplantation with CD34 + -positive selection; Allo-PBT = allogeneic peripheral blood transplantation with unmodified apheresis; No = number of patients; AML = acute myeloid leukemia; RAEB = refractory anemia with excess of blasts; RAEBt = refractory anemia with excess of blasts in transformation; CML = chronic myeloid leukemia; MDS = myelodysplastic syndrome; D = donor; P = patient; Cy = cytoxan; TBI = total body irradiation; a Grimwade et al. 36 
Donors
HLA-identical sibling donors (Table 1) received G-CSF at a median dose of 10 g/kg/day subcutaneously for 4 to 7 days. On days 5 to 8, donors underwent a median of 10 liters leukapheresis with a continuous cell separator.
GVHD prophylaxis
In the allo-PBT/CD34 ϩ group, CD34 ϩ cells were positively selected using an immunoadsorption biotin-avidin column (Ceprate SC System; CellPro Inc, Bothell, WA, USA) in 34 cases (68%), indirect immunomagnetic beads by means of Isolex 300 (Isolex 300; Baxter, Munich, Germany) in 13 cases (26%), or CliniMacs (CliniMACS; Miltenyi Biotec, Bergisch Gladbach, Germany) in three (6%) cases. In cases in which CD34
ϩ selection was performed with indirect immunomagnetic beads, CD3 ϩ cells were added to the graft to achieve a similar quantity of T cells to that infused using the immunoadsorption biotin-avidin column. The CD34 ϩ -positive fraction was infused to the patients, with previous cryopreservation in 12 cases, as the sole source of progenitor cells. The standard GVHD post-transplant prophylaxis consisted of cyclosporine A (CsA) alone or CsA plus steroids in the TCD group, and of cyclosporine plus methotrexate (MTX) in the unmodified allo-PBT. CsA was started at 1.5 mg/kg intravenously every 12 h from day −1 and adjusted to maintain therapeutic blood levels of 250-400 ng/ml, and methylprednisolone 0.5 mg/kg days ϩ7 to ϩ14, 1 mg/kg days ϩ15 to ϩ28, and tapering the doses afterwards. MTX was given at the usual dose of 15 mg/m 2 on day 1, and 10 mg/m 2 on day 3 and 6. CsA dose was reduced if renal function decreased, regardless of CsA blood levels. CsA was given orally as soon as oral mucositis disappeared, and was stopped by day 180 after transplantation.
Historical control group
The control group comprised 50 adult patients treated with unmodified allo-PBT from HLA-identical sibling donors, as a first transplant. Each patient from the allo-PBT/CD34 ϩ group was matched with a patient from the allo-PBT group fulfilling three main criteria: age (±5 years of difference), diagnosis, and phase of the disease at transplant. Comparison between groups is shown in Table 1 .
Evaluation and definitions
Engraftment was documented by increasing neutrophil and platelet counts unsupported by transfusions. Time to neutrophil engraftment was assessed by determining the number of days after day 0 for patients to achieve Ͼ500/l. Time to platelet engraftment was assessed by determining the number of days after day 0 to maintain an untransfused platelet count of Ͼ20 000/l or greater. The diagnosis and grading of acute and chronic GVHD was established according to the Seattle criteria. 24 Chronic GVHD was defined as the presence of GVHD after day 100. Renal and hepatic toxicity was established according to the WHO criteria, and mucositis and veno-occlusive disease (VOD) according to Bearman's criteria. 25 Transplant-related mortality (TRM) was defined as death due to causes different from neoplastic relapse.
Statistical methods
Results were analyzed as of April 2001. Student's t-test with two-sided P values, U Mann-Whitney, chi-square with continuity correction, and Fisher's exact test (two tails) were used when indicated. Actuarial curves were obtained by the Kaplan-Meyer method and statistically compared using the Mantel-Cox test. Statistical studies were performed by means of SPSS 6.1 (1994) or Statistica 5.1 (1997) statistical software.
Results
Engraftment
All patients reached an absolute neutrophil count (ANC) of 500 neutrophils per l and an untransfused platelet count of Ͼ20 000/l. The median day to achieve an ANC Ͼ500/l in the allo-PBT/CD34
ϩ and allo-PBT groups was 13 (range [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and 14 (range 10-33), respectively (P ϭ 0.06). The median day to achieve an untransfused platelet count of Ͼ20 000/l in the allo-PBT/CD34 ϩ and allo-PBT groups was 12 (range 4-50) and 13 (range 9-34), respectively (P ϭ 0.04). There were no differences between groups in the median day to reach ANC Ͼ1000/l (15 days in both groups) and platelet count of Ͼ50 000/l (19 days vs 15 days, respectively) (P ϭ NS). Two patients, both from the allo-PBT/CD34 ϩ group, developed late graft failure.
Acute and chronic GVHD
The incidence of acute GVHD grades II to IV was 16% in the allo-PBT/CD34 ϩ group and 42% in the allo-PBT group (P ϭ 0.003). The incidence of grades III to IV of acute GVHD was 6% in allo-PBT/CD34 ϩ patients and 24% in allo-PBT patients (P ϭ 0.02). The actuarial probability for acute GVHD clinical grade II-IV in the allo-PBT/CD34 ϩ and allo-PBT recipients was 16% (95%CI: 6-26%) vs 41% (95%CI: 29-57%), (P ϭ 0.002) (Figure 1a) . Extensive chronic GVHD occurred in eight out of 47 (17%) patients at risk receiving allo-PBT/CD34 ϩ and in 17 out of 41 (41%) receiving allo-PBT (P ϭ 0.02). The actuarial probability for extensive chronic GVHD in the allo-PBT/CD34 ϩ and allo-PBT recipients was 22% (95%CI 8-36) vs 47% (95%CI 31-63) (P ϭ 0.01) (Figure 1b) .
Toxicity, morbidity, and mortality
As compared with the allo-PBT group, recipients of allo-PBT/CD34 ϩ had less toxicity associated with the transplant (Table 2 ). The incidence of VOD tended to be lower in the allo-PBT/CD34 ϩ group (7% vs 20%; P ϭ 0.06). The performance status of the patients at the last visit was also better in the allo-PBT/CD34 ϩ group (median Karnofsky index of 97% vs 88%; P ϭ 0.04) ( vation was more frequently seen in the allo-PBT/CD34 ϩ group (60% vs 34%; P ϭ 0.03), although no single patient developed CMV disease in that group (Table 2) . Among allo-PBT/CD34 ϩ patients, 17 (34%) died, and among allo-PBT patients, 23 (46%). Eight patients (16%) relapsed in the allo-PBT/CD34
ϩ group, and all of them died. Nine patients (18%) relapsed in the allo-PBT group, and seven of them died. The incidence of fatal infections was very similar between groups: three patients died due to infection in the allo-PBT group, all of them in the setting of either severe acute or chronic GVHD, and five in the allo-PBT/CD34 ϩ group (Table 2) . Nine out of 50 (18%) patients who received an allo-PBT/CD34 ϩ died of treatment-related complications, as compared to 15 of 50 (30%) who received an allo-PBT (Table 2) . GVHD was the most frequent cause of death (10 patients; 20%) in the unmodified group, six due to acute GVHD and four due to chronic GVHD. In the allo-PBT/CD34 ϩ group, three patients (6%) died as a result of GVHD (two acute and one chronic). 
Transplant-related mortality, relapse rate, and diseasefree survival
In the entire group, the actuarial probability of TRM, relapse, and DFS for recipients of allo-PBT/CD34 ϩ and of allo-PBT was 20% vs 33% (P ϭ 0.1), 22% vs 25% (P ϭ 0.8), and 61% vs 48% (P ϭ 0.1), respectively. As shown in Table 1 , the median time from diagnosis to transplant in CML patients was 3 years in the allo-PBT/CD34 ϩ group as compared with 1 year in the allo-PBT group, respectively (P ϭ 0.008). For this reason, analysis of the clinical outcome was performed separately in CML patients and in AML/MDS patients. In CML patients, the actuarial probability of TRM, relapse, and DFS for recipients of allo-PBT/CD34 ϩ and of allo-PBT was 19% vs 24% (P ϭ 0.7), 33% vs 15% (P ϭ 0.2), and 62% vs 65% (P ϭ 0.8), respectively. For AML/MDS patients, the actuarial probability of TRM, relapse, and DFS for recipients of allo-PBT/CD34 ϩ and of allo-PBT is shown in Figures 2, 3 and 4 , respectively. 
Discussion
Transplant-related mortality continues to be an important setback in allo-BMT. The expectations that mortality associated with allografts would be reduced by using PBPC have been fulfilled in patients with advanced leukemia but, unfortunately, it appears that this might not be the case in those in early phase of their disease. 9, 14 This might be due, among other reasons, to an increased frequency of chronic GVHD. [6] [7] [8] [9] [10] [11] TCD of the graft is the most effective method to decrease chronic GVHD. 15 It may, therefore, be inferred that the use of allo-PBT/CD34 ϩ might improve the outcome of the patients by maintaining a rapid engraftment without the offset of a high incidence of chronic GVHD. This study attempts to elucidate the advantages and disadvantages of allo-PBT/CD34
ϩ by comparing it with a control group of allo-PBT.
Whereas it is accepted that TCD of bone marrow decreases the incidence of both acute and chronic GVHD, 15 the impact of allo-PBT/CD34
ϩ on the incidence of GVHD is controversial. Our group, as well as others, has reported a low incidence of this complication after allo-PBT/CD34 ϩ , [19] [20] [21] while in the experience of others severe GVHD after this procedure continues to be a problem. 22, 23 In the comparative study herein reported, the actuarial prob-ability of severe acute and extensive chronic GVHD was significantly lower in the allo-PBT/CD34 ϩ group than in the allo-PBT group.
As far as toxicity is concerned, in the allo-PBT/CD34 ϩ group we observed lesser nephrotoxicity, hepatotoxicity, mucositis, lower incidence of veno-occlusive disease, and better performance status at the last follow-up. This is most likely due to the fact that since allo-PBT/CD34 ϩ patients receive a T cell-depleted graft, they do not require MTX post transplant for GVHD prophylaxis, and that they had a lower incidence of GVHD.
As a result of TCD of the allograft, there is a slow recovery of CD4 ϩ lymphocytes during the first 6 months after the transplant, which could be related to a high probability of severe infections. 26 On the other hand, recipients of unmodified allografts have a higher incidence of GHVD, with this making necessary a strong immunosuppressive treatment. It is not surprising, therefore, that in our study there were no differences in the incidence of fatal infections between both groups (Table 2) . One concern with TCD of the allograft is the potential increase of CMV infections. 27 Although in this study CMV reactivation was more frequently observed in patients submitted to allo-PBT/CD34 ϩ , none of them developed CMV disease. In fact, the patient who died as a result of CMV infection had received an unmodified allograft, and this complication was concomitant with severe GVHD.
A major problem with TCD is that the clinical benefit of decreasing GVHD can be offset by an increased relapse rate. 15 Indeed, that is the case in patients with CML, in whom an increased relapse rate after TCD transplantation, as well as a powerful antileukemic effect of donor lymphocyte infusions (DLI) has been observed. 15, 28, 29 However, in patients with AML or RAEB/RAEBt, the effect of TCD or DLI on disease recurrence is less important. 15, [28] [29] [30] [31] [32] In our series, AML/MDS patients receiving an allo-PBT/CD34 ϩ had an actuarial probability of relapse very similar to those treated with allo-PBT. Other factors may also be important to cure leukemia by allogeneic transplantation. Thus, the incidence of relapse decreases when the intensity of the conditioning regimen is increased, 33, 34 and when CsA alone, instead of CsA plus MTX, is used. 35 There were no significant differences in the outcome of CML patients in both groups. However, the median time from diagnosis to transplant in CML patients was 3 years in the allo-PBT/CD34
ϩ group as compared with 1 year in the allo-PBT group (P ϭ 0.008), with this precluding a formal comparative survival analysis in such patients. As far as AML/MDS patients are concerned, there was a trend for a lower TRM in the allo-PBT/CD34 ϩ group, which was statistically significant within 100 days of transplant. This difference was mainly due to the high GVHD-related death rate in the allo-PBT group. We also observed an improved DFS in the allo-PBT/CD34
ϩ group for patients with AML/MDS. The low relapse rate and the relatively low TRM associated with allo-PBT/CD34 ϩ largely account for the positive outcome in AML/MDS patients.
To summarize, the results of this study suggest that allo-PBT/CD34
ϩ is related to a lower incidence of both severe acute and extensive chronic GVHD and to lesser toxicity Bone Marrow Transplantation and morbidity. Moreover, for AML/MDS patients this was achieved with an improved DFS.
